Please login to the form below

Not currently logged in
Email:
Password:

Potenza Therapeutics

This page shows the latest Potenza Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib

Oncology is a key priority for Astellas, and along with the Ganymed buy, it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics last year, and followed it up with ... a $300m licensing deal with Immunomic Therapeutics.

Latest news

  • Astellas buys Ganymed to boost immuno-oncology pipeline Astellas buys Ganymed to boost immuno-oncology pipeline

    Last year it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics and followed it up with a $300m licensing deal with Immunomic Therapeutics.

  • Astellas signs up to immuno-oncology deal Astellas signs up to immuno-oncology deal

    Astellas Pharma has signed a new and exclusive R&D deal with biotech firm Potenza Therapeutics in the growing new area of immuno-oncology. ... First generation immuno-oncology therapeutics have demonstrated meaningful clinical benefit to patients with

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics